Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 10/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | F13A1 | P00488 | 1/20 | 0.61 |
| ▸ | TGM1 | P22735 | 1/20 | 0.61 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.53 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439369 | 0.85 | TGM2 (0.79) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL14394824 | 0.85 | ALDH1A1 (0.65) | TGM2LMNAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL6358305 | 0.84 | TGM2 (0.71) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL17327878 | 0.82 | TGM2 (0.63) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL890715 | 0.82 | TGM2 (0.68) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL20691193 | 0.81 | TGM2 (0.62) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL5037749 | 0.81 | TGM2 (0.67) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL6357758 | 0.81 | TGM2 (0.61) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL11759969 | 0.81 | SMN1; SMN2 (0.68) | LMNAMAPTSMN1; SMN2NPC1RAB9A | |
| Hydroxyl Radical SCHEMBL28150321 | 0.81 | TGM2 (0.66) | TGM2LMNAF13A1TGM1TGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121137909-A | Non-woven fabric made of fungus grass fibers | 新乡化纤股份有限公司 | 2025-12-16 | — | — | CN | disclosed |
| WO-2024086664-A2 | COVALENT INHIBITORS OF WILD-TYPE AND MUTANT PI3K AND METHOD OF USES THEREOF | TOTUS MEDICINES INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2023183936-A2 | COMBINATION THERAPY OF A PI3K INHIBITOR AND KRAS INHIBITOR AND METHODS OF USE THEREOF | TOTUS MEDICINES INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-113230240-B | 1,3-diphenylprop-2-en-1-one derivative and application thereof | 广州医科大学 | 2022-12-27 | — | — | CN | disclosed |
| US-11325910-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| CN-113230240-A | 1, 3-diphenylprop-2-en-1-one derivative and application thereof | 广州医科大学 | 2021-08-10 | — | — | CN | disclosed |
| CN-109091472-B | Application of chalcone analogue containing alpha, beta unsaturated ketone in preparing anti-lung cancer medicine | 温州医科大学 | 2021-06-29 | — | — | CN | disclosed |
| WO-2021055747-A1 | THERAPEUTIC CONJUGATES | TOTUS MEDICINES INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20200277292-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-6057451-A | AMINOTHIAZOLE DERIVATIVES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0871619-A1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997024343-A1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| EP-0379305-B1 | Low odor adhesive compositions | MINNESOTA MINING & MFG (US) | 1994-05-11 | — | — | EP | disclosed |
| US-4945006-A | UNSATURATED CYCLIC AMIDES, ANAEROBIC PROCESS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1990-07-31 | — | — | US | disclosed |
| EP-0379305-A1 | Low odor adhesive compositions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1990-07-25 | — | — | EP | disclosed |
| EP-0120558-B1 | ANTIHYPERTENSIVE N-PIPERAZINYLALKANOYLANILIDES | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1989-03-08 | — | — | EP | disclosed |
| US-4510140-A | HYPOTENSIVE AGENTS; ANTHIHISTAMINES; ANALGESICS; SEDATIVES | RECORDATI S.A. (CH) | 1985-04-09 | — | — | US | disclosed |
| EP-0074768-A2 | Alkanoylanilides | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1983-03-23 | — | — | EP | disclosed |
| US-4302484-A | Polymers crosslinkable by electron beams | BAYER AKTIENGESELLSCHAFT (DE) | 1981-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325910-B2 | Inhibitors of cyclin-dependent kinases | CDK3, CDK13, CDK1 | TGM2 3990/4885LMNA 1244/4885F13A1 1192/4885 |
| US-20200277292-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | TGM2 3990/4885LMNA 1244/4885F13A1 1192/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | TGM2 3684/4885LMNA 3321/4885F13A1 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.